ArticleFrontiers in pharmacology2026
Microglial metabolic reprogramming drives the therapeutic effects of bavachinin on brain network function and memory in Alzheimer's disease.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and pervasive cognitive decline. Bavachinin, a natural flavonoid derived from the traditional medicinal herb Psoralea corylifolia, has previously been demonstrated to inhibit Aβ aggregation Methods: In this study, we systematically evaluated the therapeutic efficacy of bavachinin on AD-associated pathology, cortical slow-wave activity (SWA), and behavioral phenotypes in 5xFAD transgenic mice. We utilized behavioral assessments to evaluate learning and memory, mesoscopic wide-field calcium imaging to assess cortical network dynamics, and histological analyses to measure cerebral Aβ deposition. Furthermore, pharmacological inhibition was employed to investigate the mechanistic role of mitochondrial oxidative phosphorylation (OXPHOS). Results: Behavioral assessments revealed that bavachinin administration significantly rescued deficits in learning and memory. Mesoscopic wide-field calcium imaging further demonstrated that bavachinin substantially enhanced the synchrony of cortical SWA while reducing its frequency in 5xFAD mice, indicating a restoration of network-level dynamics. Histological analyses confirmed a marked reduction in cerebral Aβ deposition, which occurred independent of Aβ production pathways. Mechanistically, bavachinin bolstered microglial Aβ phagocytosis and chemotactic migration by promoting mitochondrial OXPHOS, thereby revitalizing cellular energy metabolism. Notably, pharmacological inhibition of OXPHOS partially abrogated the therapeutic benefits of bavachinin, suggesting that the augmentation of mitochondrial function is a requisite for its anti-AD effects. Discussion: In summary, bavachinin alleviates cognitive impairment and neuropathology in AD model mice by driving microglial metabolic reprogramming and facilitating Aβ clearance. These findings highlight its robust potential as a therapeutic candidate for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.